Topic
FDA approval
1 stories related to this topic, newest first.
Statfinance9 hrs ago
Revolution Medicines' Daraxonrasib Succeeds in Phase 3 Trial for Pancreatic Cancer
Revolution Medicines announced that its targeted pill daraxonrasib met primary and secondary endpoints in a Phase 3 trial for metastatic pancreatic cancer patients. The drug extended median survival to 13.2 months compared to 6.7 months with chemotherapy and reduced the risk of d…
ST